返回 
加入收藏
不同剂量溴隐亭对催乳素瘤临床疗效、血清催乳素水平及肿瘤体积的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 不同剂量溴隐亭对催乳素瘤临床疗效、血清催乳素水平及肿瘤体积的影响 |
| TITLE： | |
| 摘要： | 目的：探讨不同剂量溴隐亭治疗催乳素瘤的临床疗效、对血清催乳素（PRL）水平和肿瘤体积的影响及安全性。方法：选取2015年1－12月我院收治的催乳素瘤患者60例为研究对象，按照随机数字表法分为A组和B组，各30例。两组患者均餐中口服甲磺酸溴隐亭片，A组患者首次给药剂量为2.5 mg/d，3 d后增至3.75 mg/d，服用2～3 d后每周增加2.5 mg至血清PRL水平得到控制，剂量恢复至3.75 mg/d。B组患者首次给药剂量为1.25 mg/d，3 d后增至2.5 mg/d，服用2～3 d后每周增加1.25～2.5 mg至血清PRL水平得到控制，剂量恢复至2.5 mg/d。两组患者均连续治疗3个月。观察两组患者的临床疗效、治疗前后的血清PRL水平和肿瘤长径，并记录不良反应发生情况。结果：A组患者临床总有效率（83.33％）较B组（66.67％）高，但差异无统计学意义（P＞0.05）。治疗前，两组患者血清PRL水平和各类型肿瘤的长径比较，差异均无统计学意义（P＞0.05）。治疗1、2个月，两组患者血清PRL水平均较治疗前明显降低，且A组明显低于B组，差异均有统计学意义（P＜0.05）；治疗3个月，两组患者血清PRL水平均较治疗前明显降低，但组间比较差异并无统计学意义（P＞0.05）。治疗后，两组患者各类型肿瘤的长径均明显减小，A组患者大腺瘤和巨大腺瘤的长径均明显小于B组，差异均有统计学意义（P＜0.05）；但A组患者的微腺瘤长径与B组比较，差异无统计学意义（P＞0.05）。A组患者的不良反应发生率（12例，40.00％）明显高于B组（5例，16.67％），差异有统计学意义（P＜0.05）。结论：增大溴隐亭的剂量对催乳素瘤的临床疗效无显著影响，但可缩短患者血清PRL水平恢复正常的时间、缩小肿瘤体积，而其不良反应发生率随剂量增大而增加。 |
| ABSTRACT： | OBJECTIVE： To investigate clinical efficacy and safety of different dosages of bromocriptine in the treatment prolactinoma， and its effects on serum prolactin （PRL） and tumor volume. METHODS： A total of 60 patients with prolactinoma were selected from our hospital during Jan.-Dec. 2015 as research objects， and then divided into group A and B according to random number table， with 30 cases in each group. Both groups were given Bromocriptine mesilate tablets orally during meal. Group A was given medicine with initial dose of 2.5 mg/d， increasing to 3.75 mg/d 3 d later， increasing by 2.5 mg every week after 2-3 d， and then recovering to 3.75 mg/d till serum PRL level had been controlled. Group B was given medicine with initial dose of 1.25 mg/d， increasing to 2.5 mg/d 3 d later， increasing by 1.25-2.5 mg every week after 2-3 d， and then recovering to 2.5 mg/d till serum PRL level recovered to normal. Both groups were treated for consecutive 3 months. Clinical efficacies as well as serum level of PRL and tumor size were observed in 2 groups， and the occurrence of ADR was recorded. RESULTS： The total response rate of group A （83.33％） was higher than that of group B （66.67％）， without statistical significance （P＞0.05）. Before treatment， there was no statistical significance in serum level of PRL and tumor size between 2 groups （P＞0.05）. After 1， 2 months of treatment， serum levels of PRL in 2 groups were decreased significantly， and the group A was significantly lower than the group B， with statistical significance （P＜0.05）. After 3 months of treatment， serum levels of PRL in 2 groups were decreased significantly compared to before treatment， but there was no statistical significance between 2 groups （P＞0.05）. After treatment， tumor size of 2 groups were decreased significantly， and large adenoma and giant adenoma size in group A were significantly smaller than group B， with statistical significance （P＜0.05）. There was no statistical significance in microadenoma size between group A and B （P＞0.05）. The incidence of ADR in group A （12 cases， 40.00％） was significantly higher than group B （5 cases， 16.67％）， with statistical significance （P＜0.05）. CONCLUSIONS： Increasing dosages of bromocriptine no significant influence on therapeutic effect of prolactinoma，but it can shorten the time of serum PRL level back to normal， and reduce the tumor size. The incidence of adverse reactions increase with the dosage. |
| 期刊： | 2017年第28卷第26期 |
| 作者： | 王雯，姚伟峰 |
| AUTHORS： | WANG Wen，YAO Weifeng |
| 关键字： | 甲磺酸溴隐亭；催乳素瘤；临床疗效；血清催乳素；剂量 |
| KEYWORDS： | Bromocriptine mesilate； Prolactinoma； Clinical efficacy； Serum prolactin； Dose |
| 阅读数： | 307 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
